

In the claims:

1-32. (cancelled)

33. (previously presented) An antibody or fragment thereof which binds to a B7RP1 polypeptide as set forth in Figure 2A (SEQ ID NO:7) or a mature form thereof.

34. (previously presented) An antibody or fragment thereof which binds to a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or a mature form thereof.

35. (previously presented) An antibody or fragment thereof which binds to a B7RP1 polypeptide as set forth in Figure 12A (SEQ ID NO:17) or a mature form thereof.

36. (previously presented) An antibody or fragment thereof which specifically binds to a mature form of a B7RP1 polypeptide as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

37. (previously presented) An antibody or fragment thereof which binds to a mature form of a B7RP1 polypeptide as set forth in Figure 12A (SEQ ID NO:17) and to a mature form of a B7RP1 polypeptide as set forth in Figure 2A (SEQ ID NO:7).

38. **(currently amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a membrane-associated form of a B7RP1 polypeptide of as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

39. **(currently amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to a soluble form of a B7RP1 polypeptide of as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

40. **(currently amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which binds to an extracellular domain, or fragment thereof, of a B7RP1 polypeptide of as set forth in Figure 3A (SEQ ID NO:12) or Figure 12A (SEQ ID NO:17).

41. (previously presented) The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely blocks the binding of B7RP1 to CRP1.

42. **(currently amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which is an **agonist** antibody that increases B7RP-1 mediated ~~immune~~ T cell costimulatory activity.

43. **(currently amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which is an **antagonist** antibody that decreases B7RP-1 mediated ~~immune~~ T cell costimulatory activity.

44. **(currently amended)** The antibody or fragment of Claims 34, 35, 36 or 37 which partially or completely inhibits B7RP-1 mediated ~~immune~~ T cell costimulatory activity.

45. (previously presented) An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6).

46. (previously presented) An antibody or fragment thereof which binds to a polypeptide encoded by the nucleotide sequence as set forth in Figure 3A (SEQ ID NO: 11) or Figure 12A (SEQ ID NO: 16).

47. **(currently amended)** An antibody or fragment which binds to a soluble form of B7RP1, wherein B7RP1 is encoded by the nucleic acid of as set forth in Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO:16).

48. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a monoclonal antibody.

49. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a chimeric antibody.

50. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a single chain antibody.

51. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a bispecific antibody.

52. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a CDR-grafted or humanized antibody.

53. (previously presented) The antibody of Claims 34, 35, 36 or 37 which is a human antibody.

54. (previously presented) A pharmaceutical composition comprising the antibody of Claims 34, 35, 36 or 37 and a carrier, diluent, and/or excipient.